[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fmaT9d8J7mcNCPVPNxeuGTKS9_fKLUq2Ph1qZ5uGtNPE":8,"$fljyl-Zcwz8hnhp8U1m5RKVeveSfuzMWU6uV88pwjgnM":55,"$fbYR4HHz-vSgHxa2ua1zZTNLEuLyTCSXWm8wwdKjmCeo":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65762,869175,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//nuLUzB4GAI2Ye2KfylUD1xt9kYOe29It.png","李雯","东港市中心医院","肿瘤科","主治医师",17,0,"直肠癌局晚期药物治疗实用指南","","https://ystcdn.venuertc.com/venue/AI/416d649a-48a7-4602-9b1c-df273126e90d.jpg","\u003Cdiv id=\"material_title\" class=\"matrl-drug-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">直肠癌局晚期药物治疗实用指南\u003C/h2>\n  \u003Cp class=\"matrl-drug-intro\">谈到晚期肿瘤治疗，人们常会想到“化疗”“靶向”“免疫”等词，其实每一种药物背后都有许多操作细节需要关注，无论是静脉注射还是口服，关键都在于用得对、避开风险。本文聚焦奥沙利铂、伊立替康、西妥昔单抗等常用药物，梳理7个核心使用要点，帮助家庭和患者搞清如何安全高效用药。🤓\u003C/p>\n\u003C/div>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg1\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 奥沙利铂、伊立替康、西妥昔单抗：成分和剂型小知识\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>\u003Cb>奥沙利铂\u003C/b>：第三代铂类化疗药，常规以注射液形式使用。\u003C/li>\n      \u003Cli>\u003Cb>伊立替康\u003C/b>：拓扑异构酶 I 抑制剂，多为静脉输注。\u003C/li>\n      \u003Cli>\u003Cb>西妥昔单抗\u003C/b>：抗EGFR靶向抗体，静脉滴注为主。\u003C/li>\n      \u003Cli>\u003Cb>剂型特点\u003C/b>：三者均为注射剂，无口服剂型，必须在专业场所输注。\u003C/li>\n      \u003Cli>明确剂型是安全用药的前提——家中不可私自配制或注射。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"matrl-note\">正确做法：用药前应核查药品外包装及批号，有疑问及时向药师咨询。\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg2\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 药物作用机制简析：用得明白，风险可控 💡\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>奥沙利铂：通过与细胞DNA结合，抑制细胞分裂进程。\u003C/li>\n      \u003Cli>伊立替康：阻断DNA的拓扑异构环节，影响细胞增殖。\u003C/li>\n      \u003Cli>西妥昔单抗：专门结合细胞表面EGFR受体，切断生长信号通路。\u003C/li>\n      \u003Cli>三者联合时形成协同效应，有利于增强总体疗效（Van Cutsem et al., 2009）。\u003C/li>\n    \u003C/ul>\n    \u003Cp>说明：了解作用机制有助于把握为什么会出现相关副作用，如过敏反应或骨髓抑制。\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg3\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用药方法大盘点：时间、顺序、操作流程不可马虎 ⏳\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>三种药均采用静脉输注方式，常在医院化疗室完成。\u003C/li>\n      \u003Cli>输注顺序需遵医嘱，一般为奥沙利铂→伊立替康→西妥昔单抗，每次输液需间隔，避免药物混合。\u003C/li>\n      \u003Cli>用药前需测量血压、体温，观察有无皮疹或早期过敏表现。\u003C/li>\n    \u003C/ul>\n    \u003Cspan>正确做法：用药当天应适量进食、水分充足，勿空腹接受输液。每次化疗前建议与护士确认药品名称和批号。\u003C/span>\n    \u003Cdiv class=\"matrl-casebox\">\n      \u003Cb>案例：\u003C/b>有位患者接受奥沙利铂时出现皮肤红痒，经暂停输液后调整方案，成功避免严重过敏反应。\n    \u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg4\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 用药剂量和间隔：安全性与疗效的平衡点\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>奥沙利铂和伊立替康的剂量按体表面积（BSA）计算，西妥昔单抗的常规剂量为400mg/m²首次，随后250mg/m²每周一次（参考：Van Cutsem et al., JCO 2009）。\u003C/li>\n      \u003Cli>周期通常为两周或三周一周期，具体方案由医生根据个人耐受性与不良反应调整。\u003C/li>\n      \u003Cli>用药间隔必须严格遵守，不可随意提前或推迟，期间需监测血象。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"matrl-note\">正确做法：按照医嘱回院复查，千万不可擅自延长或缩短治疗周期。\u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg5\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用：联合用药如何避坑？\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>奥沙利铂与其他铂类药不可同时使用。\u003C/li>\n      \u003Cli>伊立替康与强效CYP3A4抑制剂（如某些抗生素）合用时需谨慎，可能增加毒性（Gupta et al., 2000）。\u003C/li>\n      \u003Cli>西妥昔单抗应避免与免疫抑制剂同用，以防增加感染风险。\u003C/li>\n      \u003Cli>联合化疗时对于患者肝肾等重要器官功能要严格监测。\u003C/li>\n    \u003C/ul>\n    \u003Cspan>需要注意：用药前如有慢性药物史，应主动告知医生所有已用药品，避免相互作用。\u003C/span>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg6\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 特殊人群用药调整：老年人、肾功能减退患者该怎么做？👵👨‍🦳\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>奥沙利铂肾排泄，肾功能不全者需减量。\u003C/li>\n      \u003Cli>伊立替康在肝脏代谢，肝功能不全者需慎用或调整。\u003C/li>\n      \u003Cli>西妥昔单抗无明确肾毒性，但有皮疹风险，老年人更需观察。\u003C/li>\n      \u003Cli>高龄患者用药建议从低剂量逐步加量，密切监测血象和肝肾功能。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"matrl-casebox\">\n      \u003Cb>案例：\u003C/b>一位老年患者因肾功能减退，奥沙利铂剂量减半后，骨髓抑制明显减少。\n    \u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg7\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 常见不良反应与处理方法：发现早、处理快才安全 🚨\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>奥沙利铂：常见为血小板减少、周身皮疹和过敏反应。输液时如出现红、痒或呼吸困难，须立即停药。\u003C/li>\n      \u003Cli>伊立替康：腹泻较多见，用药期间需备止泻药。\u003C/li>\n      \u003Cli>西妥昔单抗：皮疹发生率高，1级皮疹可外用药，严重时需停药。\u003C/li>\n      \u003Cli>骨髓抑制：三药均可能导致白细胞、血小板下降，定期查血是必须的（Douillard et al., 2000）。\u003C/li>\n    \u003C/ul>\n    \u003Cspan>正确做法：出现发热、出血或皮疹须立刻联系医师，不要拖延。\u003C/span>\n    \u003Cdiv class=\"matrl-casebox\">\n      \u003Cb>案例：\u003C/b>临床上使用西妥昔单抗期间，患者出现皮疹，经外用药处理后症状缓解，未影响继续治疗。\n    \u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg8\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 药品储存与有效期：一小步守住大安全🔒\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>所有注射液均应在阴凉（2-8℃）、避光环境储存，切勿冷冻或高温。\u003C/li>\n      \u003Cli>开封后未用完的药品需妥善丢弃，不可继续保存使用。\u003C/li>\n      \u003Cli>药品过期坚决不可再用，有风险时请按说明书处理。\u003C/li>\n    \u003C/ul>\n    \u003Cspan>特别提醒：家中如有剩余药品务必送至医保定点机构由药师处理，切勿随意丢弃。\u003C/span>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg9\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 漏服与过量应对技巧：灵活补救，谨慎处置\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cul>\n      \u003Cli>奥沙利铂、伊立替康、西妥昔单抗为医院用药，漏服基本不存生自我补救问题，必须回院重新安排方案。\u003C/li>\n      \u003Cli>如误用过量，可能加剧骨髓抑制或过敏反应，务必立即就医。\u003C/li>\n      \u003Cli>服药期间如分不清药量，千万不要自行加药或补药。\u003C/li>\n    \u003C/ul>\n    \u003Cspan>要牢记：出现异常情况只认专业人员，绝不自行处理。\u003C/span>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section matrl-conclusion\">\n  \u003Ch2 class=\"matrl-drug-subtitle matrl-bg10\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：用药有章法，安全有保障🏷️\u003C/h2>\n  \u003Cdiv class=\"matrl-drug-content\">\n    \u003Cp>\n      这份指南汇总了直肠癌局晚期常用药物的关键服用细节，无论是剂型选择、用药周期把控、特殊人群处理还是常见不良反应应急，都离不开每一步的用心。安全用药最重要的环节始终是“知药、懂药、问药”，出现疑问或意外时及时与医师或药师沟通，远远强过盲目自处。\u003Cbr>\n      🟢 \u003Cb>再次强调：\u003C/b>务必核查药品批号和包装，严格依照方案用药，遇到任何副作用第一时间回院评估！合理用药，才是康复道路上的有力保障。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"matrl-drug-section matrl-refbox\">\n  \u003Ch3 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h3>\n  \u003Cul class=\"matrl-ref\">\n    \u003Cli>Van Cutsem, E., Kohne, C. H., Hitre, E., et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. \u003Ci>J Clin Oncol\u003C/i>, 27(37), 6637-6647.\u003C/li>\n    \u003Cli>Gupta, E., Lestingi, T. M., Mick, R., et al. (2000). Metabolic fate and pharmacokinetics of irinotecan in cancer patients. \u003Ci>Cancer Chemother Pharmacol\u003C/i>, 45(4), 279-286.\u003C/li>\n    \u003Cli>Douillard, J. Y., Cunningham, D., Roth, A. D., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. \u003Ci>Lancet\u003C/i>, 355(9209), 1041-1047.\u003C/li>\n  \u003C/ul>\n\u003C/section>\n\n\u003Cstyle>\n.matrl-drug-title {\n  text-align: center;\n  padding: 24px 0 12px 0;\n  background-color: #f6fbfc;\n  border-bottom: 2px solid #e3f1f4;\n  font-family: \"Segoe UI\", \"Arial\", sans-serif;\n}\n.matrl-drug-title h1 {\n  font-size: 38px;\n  color: #15607a;\n  font-weight: 700;\n  letter-spacing: 1px;\n}\n.matrl-drug-intro {\n  font-size: 18px;\n  color: #127177;\n  margin-bottom: 0;\n  margin-top: 8px;\n  font-style: italic;\n}\n.matrl-drug-section {\n  margin: 38px 0 0 0;\n  padding: 0 0 36px 0;\n}\n.matrl-drug-subtitle {\n  padding: 16px 28px 12px 28px;\n  margin-bottom: 0;\n  font-size: 28px;\n  font-weight: 700;\n  border-radius: 7px 7px 0 0;\n  color: #345b71;\n  border-left: 6px solid #abeaf5;\n  font-family: \"Segoe UI\", \"Arial\", sans-serif;\n  letter-spacing: 0.5px;\n}\n\n/* 淡雅背景色依次变化 */\n.matrl-bg1 {background: linear-gradient(90deg, #eaf9fa 68%, #daf4f3 100%);}\n.matrl-bg2 {background: linear-gradient(90deg, #e9fbf3 72%, #dfeeea 100%);}\n.matrl-bg3 {background: linear-gradient(90deg, #f1fafe 80%, #dbeaf7 100%);}\n.matrl-bg4 {background: linear-gradient(90deg, #fffbe9 68%, #faefd6 100%);}\n.matrl-bg5 {background: linear-gradient(90deg, #f1f0fc 70%, #dbdaf2 100%);}\n.matrl-bg6 {background: linear-gradient(90deg, #f6faea 70%, #eaf8db 100%);}\n.matrl-bg7 {background: linear-gradient(90deg, #faecea 76%, #ffe6df 100%);}\n.matrl-bg8 {background: linear-gradient(90deg, #f4fbf8 65%, #e4ede4 100%);}\n.matrl-bg9 {background: linear-gradient(90deg, #eff6fa 80%, #dbe7f6 100%);}\n.matrl-bg10 {background: linear-gradient(90deg, #eefafa 88%, #daf3ee 100%);}\n\n.matrl-drug-content {\n  background-color: #fcfdfe;\n  padding: 22px 32px 16px 32px;\n  border-bottom: 1px solid #e4eded;\n  font-size: 19px;\n  font-family: \"Segoe UI\", \"Arial\", sans-serif;\n}\n.matrl-drug-content ul {\n  list-style-type: disc;\n  padding-left: 25px;\n  margin-bottom: 13px;\n}\n.matrl-drug-content ul li {\n  margin-bottom: 9px;\n  line-height: 1.7;\n}\n.matrl-note {\n  background: #eaf7fa;\n  font-size: 17px;\n  padding: 10px 16px;\n  margin-top: 13px;\n  border-radius: 6px;\n  color: #14809c;\n}\n.matrl-casebox {\n  background-color: #f5f8fa;\n  border-left: 4px solid #b8e7f2;\n  padding: 10px 16px;\n  margin: 21px 0 0 0;\n  font-size: 17px;\n  color: #4f7585;\n  border-radius: 6px 14px 14px 6px;\n}\n.matrl-refbox {\n  background-color: #fbfdfd;\n  border-top: 2px solid #e7f2f4;\n  padding: 28px 30px 20px 30px;\n  font-size: 18px;\n  font-family: \"Segoe UI\", \"Arial\", sans-serif;\n  margin-top: 60px;\n  border-radius: 10px;\n}\n.matrl-refbox h3 {\n  font-size: 22px;\n  font-weight: 700;\n  color: #276178;\n  margin-bottom: 16px;\n  letter-spacing: 0.4px;\n}\n.matrl-refbox .matrl-ref {\n  margin: 0;\n  padding: 0 0 0 23px;\n}\n.matrl-refbox .matrl-ref li {\n  list-style-type: decimal;\n  margin-bottom: 8px;\n  font-size: 16px;\n  color: #234d56;\n  line-height: 1.75;\n}\n.matrl-conclusion {\n  border-top: 2px solid #daf3ee;\n  background: linear-gradient(90deg, #f1f9fa 86%, #daf3ee 100%);\n  padding: 32px 32px 18px 32px;\n}\n.matrl-conclusion .matrl-drug-subtitle {\n  margin-bottom: 18px;\n}\n.matrl-conclusion p {\n  font-size: 20px;\n  color: #266a77;\n  line-height: 2;\n  margin-top: 8px;\n  margin-bottom: 0;\n}\n@media (max-width: 720px) {\n  .matrl-drug-title h1 {font-size: 27px;}\n  .matrl-drug-content, .matrl-conclusion, .matrl-refbox {padding:16px 10px 16px 10px;}\n  .matrl-drug-section {margin:25px 0 0 0;}\n  .matrl-drug-subtitle {font-size:20px; padding: 10px 14px;}\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"matrl-drug-title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2e",512,"2025-09-05 13:43:52","直肠癌,晚期药物治疗,化疗,西妥昔单抗,伊立替康,奥沙利铂,安全用药,药物副作用","本指南聚焦奥沙利铂、伊立替康、西妥昔单抗的使用注意点，帮助患者及家属安全高效用药，减轻治疗风险，实现最佳治疗效果。","2025-09-09 13:20:53",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]